Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-1901
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

RAF Dimer Inhibition Enhances the Antitumor Activity of MEK Inhibitors in K‐RAS Mutant Tumors

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2020English

MEK Inhibition Induces Differentiation in RAS-Driven Rhabdomyosarcoma

Cancer Discovery
Oncology
2018English

Modulation of the Akt/Ras/Raf/Mek/Erk Pathway by A3 Adenosine Receptor

Purinergic Signalling
Molecular NeuroscienceCell BiologyMolecular BiologyCellular
2006English

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Cancer Research
Cancer ResearchOncology
2018English

Ras/Mek Signaling Suppresses Myc-Dependent Apoptosis in Cells Transformed by C-Myc and Activated Ras

Oncogene
Cancer ResearchGeneticsMolecular Biology
2000English

Blocking P53 Aggregation Restores Its Activity and Suppresses Tumors

Cancer Discovery
Oncology
2016English

Larotrectinib Has Antitumor Activity in TRK + Pediatric Solid Tumors

Cancer Discovery
Oncology
2018English

Syndecan-1 Suppresses Cell Growth and Migration via Blocking JAK1/STAT3 and Ras/Raf/Mek/Erk Pathways in Human Colorectal Carcinoma Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Antitumor Activity of MEK and PI3K Inhibitors Against Malignant Pleural Mesothelioma Cells in Vitro and in Vivo

International Journal of Oncology
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy